212 related articles for article (PubMed ID: 16320975)
1. [Feasibility of cardiopulmonary rehabilitation in patients with idiopathic pulmonary arterial hypertension treated with intravenous prostacyclin infusion therapy].
Uchi M; Saji T; Harada T
J Cardiol; 2005 Nov; 46(5):183-93. PubMed ID: 16320975
[TBL] [Abstract][Full Text] [Related]
2. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].
Nakayama T; Ishikita T; Matsuura H; Saji T
J Cardiol; 2001 Nov; 38(5):263-71. PubMed ID: 11729726
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results].
Jiménez López-Guarch C; Escribano Subias P; Tello de Meneses R; Delgado Jiménez JF; Sadia Pérez D; Velázquez Martín MT; Gómez Sánchez MA; Sáenz de la Calzada C
Rev Esp Cardiol; 2004 Oct; 57(10):946-51. PubMed ID: 15469792
[TBL] [Abstract][Full Text] [Related]
4. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial.
Hiremath J; Thanikachalam S; Parikh K; Shanmugasundaram S; Bangera S; Shapiro L; Pott GB; Vnencak-Jones CL; Arneson C; Wade M; White RJ;
J Heart Lung Transplant; 2010 Feb; 29(2):137-49. PubMed ID: 20022264
[TBL] [Abstract][Full Text] [Related]
5. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience.
Ruiz MJ; Escribano P; Delgado JF; Jiménez C; Tello R; Gómez MA; de la Calzada CS
J Heart Lung Transplant; 2006 Nov; 25(11):1353-7. PubMed ID: 17097500
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
[TBL] [Abstract][Full Text] [Related]
9. Bosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusion.
Prescrire Int; 2005 Apr; 14(76):47-50. PubMed ID: 15875338
[TBL] [Abstract][Full Text] [Related]
10. Epoprostenol treatment in children with severe pulmonary hypertension.
Lammers AE; Hislop AA; Flynn Y; Haworth SG
Heart; 2007 Jun; 93(6):739-43. PubMed ID: 17065181
[TBL] [Abstract][Full Text] [Related]
11. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
[TBL] [Abstract][Full Text] [Related]
12. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
[TBL] [Abstract][Full Text] [Related]
13. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
Barst RJ; Rubin LJ; Long WA; McGoon MD; Rich S; Badesch DB; Groves BM; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Clayton LM; Jöbsis MM; Blackburn SD; Shortino D; Crow JW;
N Engl J Med; 1996 Feb; 334(5):296-301. PubMed ID: 8532025
[TBL] [Abstract][Full Text] [Related]
14. [The effect of physical training in chronic heart failure].
Andersen K; Jónsdóttir S; Sigurethsson AF; Sigurethsson SB
Laeknabladid; 2006 Nov; 92(11):759-64. PubMed ID: 17093327
[TBL] [Abstract][Full Text] [Related]
15. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.
Garg N; Sharma MK; Sinha N
Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417
[TBL] [Abstract][Full Text] [Related]
16. Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions.
Scelsi L; Ghio S; Campana C; D'Armini AM; Serio A; Klersy C; Piovella F; Viganò M; Tavazzi L
Ital Heart J; 2004 Aug; 5(8):618-23. PubMed ID: 15554033
[TBL] [Abstract][Full Text] [Related]
17. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension.
Frantz RP; Benza RL; Kjellström B; Bourge RC; Barst RJ; Bennett TD; McGoon MD
J Heart Lung Transplant; 2008 Jul; 27(7):780-8. PubMed ID: 18582809
[TBL] [Abstract][Full Text] [Related]
18. Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study.
Fattouch K; Sbraga F; Sampognaro R; Bianco G; Gucciardo M; Lavalle C; Vizza CD; Fedele F; Ruvolo G
J Cardiovasc Med (Hagerstown); 2006 Feb; 7(2):119-23. PubMed ID: 16645371
[TBL] [Abstract][Full Text] [Related]
19. Moderate-term effect of epoprostenol on severe portopulmonary hypertension.
Kato H; Katori T; Nakamura Y; Kawarasaki H
Pediatr Cardiol; 2003; 24(1):50-3. PubMed ID: 12574979
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of prostacyclin for pulmonary hypertension in congenital heart disease.
Durongpisitkul K; Jakrapanichakul D; Laohaprasitiporn D; Soongswang J; Chanthong P; Nana A
J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S60-5. PubMed ID: 16856428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
